Info: Read More
  • 中药标准品生产商,产品定制服务
  • 辅酶Q10

    Coenzyme Q10

    辅酶Q10
    产品编号 CFN99165
    CAS编号 303-98-0
    分子式 = 分子量 C59H90O4 = 863.36
    产品纯度 >=98%
    物理属性 Yellow cryst.
    化合物类型 Quinones
    植物来源 Gibberella fujikuroi
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    辅酶Q10 CFN99165 303-98-0 10mg QQ客服:3257982914
    辅酶Q10 CFN99165 303-98-0 20mg QQ客服:3257982914
    辅酶Q10 CFN99165 303-98-0 50mg QQ客服:3257982914
    辅酶Q10 CFN99165 303-98-0 100mg QQ客服:3257982914
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • University of Perugia (Italy)
  • Leibniz-Institut für Pflanzenbiochemie (IPB) (Germany)
  • Max Rubner-Institut (MRI) (Germany)
  • University of Cincinnati (USA)
  • Nicolaus Copernicus Uniwersity (Poland)
  • University of Maryland (USA)
  • Osmania University (India)
  • Hamdard University (India)
  • Biotech R&D Institute (USA)
  • Utah State University (USA)
  • Universidade Católica Portuguesa (Portugal)
  • Kitasato University (Japan)
  • University of Limpopo (South Africa)
  • Uniwersytet Jagielloński w Krakowie (Poland)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Nutrients.2023, 15(6):1417.
  • Academic J of Second Military Medical University2018, 39(11)
  • Biomedicines.2021, 9(8):996.
  • Crystals2020, 10(3), 206.
  • Biomimetics (Basel).2022, 7(4):154.
  • Pharmacognosy Journal2019, 11(2): 369-373
  • Drug Test Anal.2018, 10(10):1579-1589
  • Vietnam Journal of Science2022, 64(2), 69-75.
  • Biomolecules2021, 11(10),1513.
  • Foods.2021, 10(11):2627.
  • Biochem Biophys Res Commun.2020, 522(1):40-46
  • Pak J Pharm Sci.2019, 32(6):2879-2885
  • Evid Based Complement Alternat Med.2021, 8855980.
  • Evid Based Complement Alternat Med.2020, 2020:8582318.
  • BMC Complement Altern Med.2017, 17(1):393
  • Phytother Res.2019, 33(3):676-689
  • Front Endocrinol (Lausanne).2020, 11:568436.
  • Evid Based Complement Alternat Med.2015, 2015:165457
  • Microchemical Journal2018, 137:168-173
  • Int J Mol Sci.2019, 20(14):E3538
  • International J of Green Pharmacy2019, 13(3)
  • Cell Chem Biol.2019, 26(1):27-34
  • Fitoterapia.2021, 153:104995.
  • ...
  • 生物活性
    Description: Coenzyme Q10, an essential cofactor of the electron transport chain, has neuroprotective effect in the cerebral ischemia via as a potent antioxidant and oxygen derived free radicals scavenger. Treatment with coenzyme Q10 in patients with myocardial infarction (MI) may be beneficial in patients with high risk of atherothrombosis. The coenzyme Q10 and alpha-lipoic acid supplementation can improve bladder function after outlet obstruction. The combination of Coenzyme Q10 and creatine may be useful in the treatment of neurodegenerative diseases such as Parkinson's disease and Huntington's Diseases. Coenzyme Q10 supplementation improves endothelial function of conduit arteries of the peripheral circulation in dyslipidaemic patients with Type II diabetes, the mechanism could involve increased endothelial release and/or activity of nitric oxide due to improvement in vascular oxidative stress.
    Targets: Akt | mTOR | PGE | TNF-α | IL Receptor | ATP
    In vitro:
    Oxid Med Cell Longev. 2015;2015:867293.
    Coenzyme Q10 Inhibits the Aging of Mesenchymal Stem Cells Induced by D-Galactose through Akt/mTOR Signaling.[Pubmed: 25789082]
    Increasing evidences indicate that reactive oxygen species are the main factor promoting stem cell aging. Recent studies have demonstrated that coenzyme Q10 (CoQ10) plays a positive role in organ and cellular aging. However, the potential for CoQ10 to protect stem cell aging has not been fully evaluated, and the mechanisms of cell senescence inhibited by CoQ10 are still poorly understood. Our previous study had indicated that D-galactose (D-gal) can remarkably induce mesenchymal stem cell (MSC) aging through promoting intracellular ROS generation.
    METHODS AND RESULTS:
    In this study, we showed that CoQ10 could significantly inhibit MSC aging induced by D-gal. Moreover, in the CoQ10 group, the expression of p-Akt and p-mTOR was clearly reduced compared with that in the D-gal group. However, after Akt activating by CA-Akt plasmid, the senescence-cell number in the CoQ10 group was significantly higher than that in the control group.
    CONCLUSIONS:
    These results indicated that CoQ10 could inhibit D-gal-induced MSC aging through the Akt/mTOR signaling.
    In vivo:
    Iran Red Crescent Med J. 2014 Dec 1;16(12):e18852.
    Coenzyme q10 administration in community-acquired pneumonia in the elderly.[Pubmed: 25763241]
    Community-acquired pneumonia (CAP) is generally considered a major cause of morbidity and mortality in the elderly. This study aimed to assess the efficacy of adjunctive coenzyme Q10 (CoQ10) in the treatment of elderly CAP.
    METHODS AND RESULTS:
    Hospitalized elderly patients with CAP (diagnosed by using defined clinical and radiological criteria) were randomized to receive oral CoQ10 (200 mg/d) or placebo for 14 days, along with antibiotics. Primary and secondary outcomes on days 3, 7, and 14 were measured. Disease severity was scored using CURB-65 index. Statistical analysis was performed using SPSS and P value < 0.05 was considered significant. We enrolled 150 patients for this research. Then, 141 patients, including 70 patients in the trial group and 71 patients in the control group were analyzed. Mean age of the trial and control groups were 67.6 ± 7.2 years and 68.7 ± 7.9 years, respectively. Clinical cure at days 3 and 7 were 24 (34.3%) and 62 (88.6%) in the trial group (P value = 0.6745) and 22 (31%) and 52 (73.2%) in the placebo group (P value = 0.0209). Patients on CoQ10 had faster defervescence (P value = 0.0206) and shorter hospital stay (P value = 0.0144) compared with the placebo group. The subgroup analysis of the patients with severe pneumonia showed differences in clinical cure at day 14. Treatment failure was less in CoQ10 group than in the placebo group (10% versus 22.5% and P value = 0.0440). Adverse events in two groups were few and similar.
    CONCLUSIONS:
    CoQ10 administration has no serious side effects and can improve outcome in hospitalized elderly CAP; therefore, we recommend it as an adjunctive treatment in elderly patients.
    Diabetologia. 2002 Mar;45(3):420-6.
    Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus.[Pubmed: 11914748 ]
    We assessed whether dietary supplementation with coenzyme Q(10) improves endothelial function of the brachial artery in patients with Type II (non-insulin-dependent) diabetes mellitus and dyslipidaemia.
    METHODS AND RESULTS:
    A total of 40 patients with Type II diabetes and dyslipidaemia were randomized to receive 200 mg of coenzyme Q(10) or placebo orally for 12 weeks. Endothelium-dependent and independent function of the brachial artery was measured as flow-mediated dilatation and glyceryl-trinitrate-mediated dilatation, respectively. A computerized system was used to quantitate vessel diameter changes before and after intervention. Arterial function was compared with 18 non-diabetic subjects. Oxidative stress was assessed by measuring plasma F(2)-isoprostane concentrations, and plasma antioxidant status by oxygen radical absorbance capacity. The diabetic patients had impaired flow-mediated dilation [3.8 % (SEM 0.5) vs 6.4 % (SEM 1.0), p = 0.016], but preserved glyceryl-trinitrate-mediated dilation, of the brachial artery compared with non-diabetic subjects. Flow-mediated dilation of the brachial artery increased by 1.6 % (SEM 0.3) with coenzyme Q(10) and decreased by -0.4 % (SEM 0.5) with placebo (p = 0.005); there were no group differences in the changes in pre-stimulatory arterial diameter, post-ischaemic hyperaemia or glyceryl-trinitrate-mediated dilation response. Coenzyme Q(10) treatment resulted in a threefold increase in plasma coenzyme Q(10) (p < 0.001) but did not alter plasma F(2)-isoprostanes, oxygen radical absorbance capacity, lipid concentrations, glycaemic control or blood pressure.
    CONCLUSIONS:
    Coenzyme Q(10) supplementation improves endothelial function of conduit arteries of the peripheral circulation in dyslipidaemic patients with Type II diabetes. The mechanism could involve increased endothelial release and/or activity of nitric oxide due to improvement in vascular oxidative stress, an effect that might not be reflected by changes in plasma F(2)-isoprostane concentrations.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 1.1583 mL 5.7913 mL 11.5827 mL 23.1653 mL 28.9566 mL
    5 mM 0.2317 mL 1.1583 mL 2.3165 mL 4.6331 mL 5.7913 mL
    10 mM 0.1158 mL 0.5791 mL 1.1583 mL 2.3165 mL 2.8957 mL
    50 mM 0.0232 mL 0.1158 mL 0.2317 mL 0.4633 mL 0.5791 mL
    100 mM 0.0116 mL 0.0579 mL 0.1158 mL 0.2317 mL 0.2896 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    4-羟基红根草对醌; 4-Hydroxysapriparaquinone CFN97936 120278-25-3 C20H26O4 = 330.4 5mg QQ客服:2056216494
    Salvisyrianone; Salvisyrianone CFN97952 250691-57-7 C20H24O3 = 312.4 5mg QQ客服:3257982914
    樱草素; Primin CFN90588 15121-94-5 C12H16O3 = 208.26 10mg QQ客服:2159513211
    2,5-二羟基-3-壬烷基-1,4-苯醌; Homoembelin CFN91184 38363-99-4 C15H22O4 = 266.3 5mg QQ客服:215959384
    恩贝灵; 恩贝酸; Embelin CFN90537 550-24-3 C17H26O4 = 294.38 20mg QQ客服:1457312923
    酸藤子醌; Rapanone CFN91185 573-40-0 C19H30O4 = 322.4 10mg QQ客服:1457312923
    α-托可醌; alpha-Tocopherolquinone CFN97235 7559-04-8 C29H50O3 = 446.7 20mg QQ客服:3257982914
    辅酶Q10; Coenzyme Q10 CFN99165 303-98-0 C59H90O4 = 863.36 20mg QQ客服:215959384
    维生素 K1; Vitamin K1 CFN90050 84-80-0 C31H46O2 = 450.7 20mg QQ客服:2056216494

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产